1. Home
  2. VRTX vs MCK Comparison

VRTX vs MCK Comparison

Compare VRTX & MCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$455.90

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Logo McKesson Corporation

MCK

McKesson Corporation

HOLD

Current Price

$916.69

Market Cap

101.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTX
MCK
Founded
1989
1833
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Other Pharmaceuticals
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.7B
101.9B
IPO Year
2006
1995

Fundamental Metrics

Financial Performance
Metric
VRTX
MCK
Price
$455.90
$916.69
Analyst Decision
Buy
Strong Buy
Analyst Count
27
13
Target Price
$526.79
$930.23
AVG Volume (30 Days)
1.3M
747.3K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
0.35%
EPS Growth
836.54
14.87
EPS
15.32
24.73
Revenue
$2,488,652,000.00
$112,084,000,000.00
Revenue This Year
$10.79
$14.97
Revenue Next Year
$10.14
$8.20
P/E Ratio
$30.10
$37.66
Revenue Growth
46.20
3.11
52 Week Low
$362.50
$633.53
52 Week High
$519.68
$999.00

Technical Indicators

Market Signals
Indicator
VRTX
MCK
Relative Strength Index (RSI) 42.72 47.01
Support Level $455.62 $796.22
Resistance Level $465.98 N/A
Average True Range (ATR) 13.17 17.27
MACD -2.82 -6.87
Stochastic Oscillator 13.47 8.67

Price Performance

Historical Comparison
VRTX
MCK

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About MCK McKesson Corporation

McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Share on Social Networks: